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The novel approach for deposition of iron oxide nanoparticles with narrow size distribution supported on different
sized graphene oxide was reported. Two different samples with different size distributions of graphene oxide (0.5 to
7 μm and 1 to 3 μm) were selectively prepared, and the influence of the flake size distribution on the mitochondrial
activity of L929 with WST1 assay in vitro study was also evaluated. Little reduction of mitochondrial activity of the
GO-Fe3O4 samples with broader size distribution (0.5 to 7 μm) was observed. The pristine GO samples (0.5 to 7 μm) in
the highest concentrations reduced the mitochondrial activity significantly. For GO-Fe3O4 samples with narrower size
distribution, the best biocompatibility was noticed at concentration 12.5 μg/mL. The highest reduction of cell viability
was noted at a dose 100 μg/mL for GO (1 to 3 μm). It is worth noting that the chemical functionalization of GO
and Fe3O4 is a way to enhance the biocompatibility and makes the system independent of the size distribution of
graphene oxide.
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In recent years, graphene, well-defined 2D honeycomb-like
network of carbon atoms, has attracted growing interest
owing to its unprecedented combination of unique elec-
trical, thermal, optical, and mechanical properties [1-6].
Graphene derivative, graphene oxide chemically exfoli-
ated from oxidized graphite, is considered as a promis-
ing material for biological applications due to its surface
functionalizability, amphiphilicity, and excellent aqueous
processability. These extraordinary properties are mainly
derived from its chemical structures composed of sp3
carbon domains surrounding sp2 carbon domain and a
wide range of functional groups such as epoxy, hydroxyl,
and carboxyl groups [7-10]. The chemical structure of
graphene oxide and large specific surface area enable
various chemical modification or functionalization and* Correspondence: kurbas@zut.edu.pl
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in any medium, provided the original work is pmake graphene oxide an excellent platform for loading
magnetic nanoparticles [11].
Magnetic nanoparticles possessing tailored surface prop-
erties and appropriate physicochemistry have been widely
investigated for various applications such as hyperthermia,
magnetic resonance imaging (MRI), tissue repair, drug de-
livery, biosensing, and bioanalysis [12-23]. In particular,
the magnetite, Fe3O4, has attracted significant attention in
the field of biotechnology and medicine because of its
strong magnetic properties and low toxicity [24-26]. The
properties of nanocrystals strongly depend on the dimen-
sion of the nanocrystals; therefore, the control of mono-
dispersed size of nanocrystals plays an important role.
Magnetic nanoparticles for the use in biomedical applica-
tions are desired to exhibit superparamagnetic properties.
The superparamagnetic nature implies that the particles
will not be attracted to each other, and so the risk of ag-
glomeration in a medical setting is minimized. Magnetite
is traditionally ferromagnetic in nature. However, as the
size decreases to 30 nm or smaller, it loses their perman-
ent magnetism and becomes superparamagnetic [27].
Safety concerns could ultimately prevent the adoption ofOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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toxicity results often contradict each other hence are an
area that needs more research.
Recently, graphene-based materials were extensively in-
vestigated for application in biosensing [28-32], imaging
[33,34], and drug delivery [35-38] as vehicles for drugs
and as high-performance electrode material for capacitive
deionization [39,40]. Cong et al. report on fabrication of
reduced graphene oxide decorated with Fe3O4 nanoparti-
cles through a high-temperature decomposition method
[41]. This system could be used as magnetic resonance
contrast agent. Shen et al. demonstrated one-step synthe-
sis of GO-Fe3O4 nanoparticle hybrid [42]. He and Gao
presented scalable, green, efficient, controllable method of
preparation of superparamagnetic, processable, and con-
ductive graphene nanosheets coated with magnetite nano-
particles [43]. He et al. showed attachment of magnetite
nanoparticles to GO surface with covalent bonding [44].
Yang et al. described GO-Fe3O4 nanoparticle hybrid sup-
porting doxorubicin hydrochloride (anticancer drug) [35].
This system could be easily removed from water by an
external magnetic field. Zheng and Li reported on fabri-
cation of a magnetite nanoparticle-decorated graphene
oxide (Fe3O4-GO) and reduced graphene oxide (Fe3O4-
rGO) loaded with β-lapachone (anticancer drug), in vitro
anticancer efficacy and cytotoxicity of obtained materials
[45]. Bai et al. presented results of study on the inductive
heating property of graphene oxide sheets decorated with
magnetite nanoparticles in AC magnetic field [46]. The
potential of the obtained nanocomposite was evaluated for
localized hyperthermia treatment of cancer cells.
Herein, we present new facile approach for production
of the monodispersed Fe3O4 nanoparticles and magnetic
attachment of magnetite nanoparticles to graphene oxide
sheets with different flake size distributions. The mean
size of the obtained magnetite nanoparticles is about
8 nm. Additionally, we performed cytocompatibility
study on the influence of these molecular hybrids on the
mitochondrial activity of L929 cell line with WST1 assay
in respect to the GO and pristine iron oxide nanoparticles.
The cellular response was verified with different concen-
tration (0.0, 3.125, 6.25, 12.5, 25.0, 50.0, 100.0 μg/mL) of
the nanomaterials.
Methods
Preparation of graphene oxide-Fe3O4 nanoparticle hybrid
Synthesis of graphene oxide
Two types of samples of graphene oxide were synthesized
by oxidation of graphite with various size of flakes (with
narrow and broad size distribution) using the modified
Hummer's method fully described elsewhere [47]. To a
mixture of 6 g KMnO4 and 1 g graphite, 120 mL of con-
centrated sulfuric acid and 15 mL of orthophosphoric acid
were poured. It was heated to 50°C and stirred for 24 h.The resulting mixture was added to ice (150 mL) with
1 mL of H2O2 (30%) and centrifuged. The separated solid
product was washed two times with water and 30% HCl
and ethanol and left for vacuum drying for 12 h at 70°C.
The sample with broad size distribution is named B-GO,
and the sample with narrow size distribution is named N-
GO.
Synthesis of magnetite nanoparticles
Magnetic Fe3O4 nanoparticles were synthesized by co-
precipitation of Fe2+ and Fe3+ aqueous salt solutions
using NH3 · H2O as the precipitating agent in order to
adjust the pH value. It should be noticed that the size,
shape, and composition of nanoparticles may be con-
trolled by means of the type of salts used, Fe2+ and Fe3+
ratio, pH, and ionic strength of the media. To synthesize
Fe3O4 nanoparticles, the solutions of 3.9 g Mohr's salt
(NH4)2Fe(SO4)2 · 6H2O in 100 mL H2O (0.1 M) and
4.8 g NH4Fe(SO4)2 · 12H2O in 100 mL H2O (0.1 M) were
prepared and mixed with a molar ratio of 1:2. Ammonia
aqueous solution was dropped into the mixture slowly
until the pH value of the solution reached 9. The
complete precipitation of Fe3O4 was expected between
pH 9 and 14. The overall reaction may be written as
follows:
NH4ð Þ2Fe SO4ð Þ2:6H2O þ 2 NH4Fe SO4ð Þ2:12H2O
þ 8 NH4OH→
→ Fe3O4⋅4H2O þ 6 NH4ð Þ2SO4 þ 14 H2O
The magnetite synthesis route was carried out under the
action of a rotating magnetic field (RMF). A liquid-filled
glass container was placed inside the three-phase stator of
an induction squirrel-cage motor which generated the
RMF. This kind of the magnetic field might be used to
augment the process intensity instead of a mechanical
mixing. One of the advantages of the RMF is the possibil-
ity to apply it to generation and control of the hydro-
dynamic states for the magnetic particle mixing systems.
In the experimental procedure, the frequency of the RMF
was equal to 50 Hz. The intensity of the magnetic field
could be 25 mT. The more detailed information about the
experimental setup and the measurements of the magnetic
field for the tested apparatus may be found here [48]. Fi-
nally, the precipitate was collected by filtration and
washed three times with deionized water and then dried.
Synthesis of graphene oxide-Fe3O4 nanoparticle hybrid
The synthesis process of GO-Fe3O4 nanocomposite is
schematically illustrated in Figure 1. Twenty milligrams
of each of graphene oxide sample (B-GO and N-GO)
was exfoliated in 60 mL H2O by ultrasonication to pro-
duce a homogeneous graphene oxide water-based sus-
pension. Then, the carboxylic groups on the graphene
Figure 1 Schematic of the synthesis of GO-Fe3O4 nanoparticle hybrid.
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succinimide (NHS) and 10 mg of 1-(3-dimethylamino-
propyl)-3-ethylcarbodiimide (EDC). The surface of iron
oxide (20 mg) was modified with oleic acid (3 mL) and
then stirred and sonicated for 1 h. The mixture of modi-
fied iron oxide and graphene oxide was stirred for 48 h.
In the next step, the mixture was filtered by a polycar-
bonate membrane and washed several times with water
and ethanol. Finally, the obtained product was dried for
12 h at 100°C. The sample with broad size distribution
of graphene oxide flakes is named B-GO-Fe3O4, and the
sample with narrow size distribution is named N-GO-
Fe3O4.
Characterization
High-resolution transmission electron microscopy (HRTEM)
(FEI Tecnai F30, Frequency Electronics Inc., Mitchel Field,
NY, USA) was employed to examine the morphology of
the samples and the size and distribution of the magnetite
nanoparticles. X-ray diffraction technique (X-ray diffract-
ometer Philips X'Pert PRO, PANalytical B.V., Almelo, The
Netherlands, Kα1 = 1.54056 Å) was used to investigate the
structure of the samples and to estimate the average size
of magnetite nanoparticles. In order to study the thickness
of obtained graphene oxide flakes and nanocomposite,
atomic force microscopy (Nanoscope V Multimode 8,
Bruker AXS, Mannheim, Germany) was employed. IR ab-
sorption spectra were collected on the Nicolet 6700 FTIR
spectrometer (Thermo Nicolet Corp., Madison, WI, USA).
In order to investigate the thermal behavior of the sam-
ples, thermogravimetric analysis was performed on the
SDT Q600 simultaneous TGA/DSC (TA Instruments Inc.,
Milford, MA, USA) under an air flow of 100 mL/min at
heating rate of 5°C/min. Raman spectra were acquired on
the inVia Raman Microscope (Renishaw PLC, New MillsWotton-under-Edge, Gloucestershire, UK) at an excitation
wavelength of 785 nm.
Cell culture
The cell line of mouse fibroblasts (L929) were seeded on
the 96-well plates at the density of 7.4 × 103 per well. Cells
were maintained using DMEM cell culture medium
(Gibco Corp., Grand Island, NY, USA) supplemented with
10% heat-inactivated fetal bovine serum (Gibco Corp.,
Grand Island, NY, USA), 0.4% streptomycin/penicillin
(Sigma-Aldrich Corp., St. Louis, MO, USA), and 2 mM
L-glutamine (Sigma-Aldrich Corp., St. Louis, MO, USA)
at 37°C, 5% CO2, and 95% humidity. The 200 μL/well final
volume of culture medium was used in experiment.
The cytocompatibility study
The cytocompatibility of nanomaterials was tested using
WST-1 Cell Proliferation Assay (Roche Applied Science,
Penzberg, Germany) [49]. The test principle is based on
the transformation of WST-1 salt [2-(4-iodophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium] into
water-soluble colored formazan by mitochondrial dehy-
drogenases [50] that are active in rapidly dividing cells
[51]. The generation of the dark yellow colored formazan
is directly correlated to the number of the metabolically
active cells; therefore, the cell number can be quantified
by the photometric detection of the formazan. There are
several similar proliferation assays using other tetrazolium
salts, such as MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide], XTT [2,3-bis(2-methoxy-4-
nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide], and
MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium] available on the
market. The main advantage of WST-1 test over those
mentioned above is the solubility of reduced WST-1 salt. It
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cells. To perform the assay, L929 cells were plated in the
96-well plates for 24 h. After incubation period from cells
seeding, N-GO, B-GO, N-GO-Fe3O4, B-GO-Fe3O4, and
Fe3O4 were introduced separately to cells with different
final concentrations (0.0, 3.125, 6.25, 12.5, 25.0, 50.0,
100.0 μg/mL) in culture medium. Cells were incubated
with nanomaterial for 24 h. Cells maintained in prepared
medium without adding tested samples were taken as a
control. To each well, 20 μL of WST-1 solution was added
and incubated for additional 30 min at 37°C. After incuba-
tion, the absorbance at 450 nm, according to manufactur-
er's instructions, was recorded on the Sunrise Absorbance
Reader (Tecan Group Ltd., Männedorf, Switzerland). All of
the experiments were conducted in triplicate.
Statistical analysis
All experiments were repeated at least three times. The
results are given in the form: mean values ± standard de-
viation (SD). All results were compared using Student's
t-test. Differences are considered significant at a level of
p < 0.05.
Results and discussion
Transmission electron microscopy (TEM) was used for
characterization of starting materials and final products.
Representative TEM images of Fe3O4, B-GO-Fe3O4, and
N-GO-Fe3O4 nanoparticle hybrid are shown in Figure 2.
Images of magnetite indicate a spherical shape of mag-
netite nanoparticles. The histogram presenting diameter
distribution of the Fe3O4 nanoparticles is placed as an
inset of Figure 2A. The diameter of the nanoparticles is
in the range of 5 to 14 nm with strong peak at 8 nm.
Uniform coverage of graphene oxide with magnetite
nanoparticles can be observed in the images of the ob-
tained nanocomposites (Figure 2B,C).
To examine the morphology of the samples and the
thickness of graphene oxide flakes, atomic force micros-
copy was employed. Atomic force microscopy (AFM) re-
sults of B-GO, N-GO, and B-GO-Fe3O4 and N-GO-Fe3O4
nanoparticle hybrid are presented in Figure 3. They indi-
cate the change in the thickness of the flakes before and
after functionalization - from 2 to 18 to 30 nm in both
kinds of hybrids due to the deposition of the nanoparticles
on graphene oxide flakes.
AFM characterization is a useful tool for estimating
the size distribution of the GO flakes. Figure 4A presents
broad size distribution of graphene oxide flakes (from
0.5 to 7 μm) whereas Figure 4B presents narrower size
distribution (from 1 to 3 μm).
In order to follow the efficiency of the covalent func-
tionalization of graphene oxide and iron oxide nanopar-
ticle, the Fourier transform infrared (FTIR) spectroscopy
was employed. Figure 5 presents FTIR spectra of GO,Fe3O4, B-GO-Fe3O4, and N-GO-Fe3O4. Figure 5A shows
spectrum of GO with following peaks: 1,078 cm−1 corre-
sponding to C-O stretching vibration mode related to the
presence of the alkoxy group, 1,180 cm−1 attributed to C-
O from the epoxy group, 1,475 cm−1 from C-OH carboxyl
group, 1,625 cm−1 associated with the presence of C = C
bond, and 1,742 cm−1 assigned to C =O stretching vibra-
tion mode in carboxyl group. Peak at 2,952 cm−1 originates
from C-H bond. This spectrum confirms the presence of
alkoxy, epoxy, and carboxyl group characteristic to gra-
phene oxide. Figure 5B depicts FTIR absorption spectrum
of Fe3O4 dominated by peaks at 570 and 1,059 cm
−1
assigned to the presence of Fe-O bonds typical to mag-
netite. In the spectra of B-GO-Fe3O4 and N-GO-Fe3O4
(Figure 5C,D, respectively) peak from Fe-O bond has
shifted from 570 to 809 cm−1 after functionalization. New
peaks at 698 and 1,259 cm−1 occurred. The first one is at-
tributed to N-H bond, and the second one is corresponded
to C-N bond. Therefore, the presented spectra provide the
proof for successful functionalization of GO with Fe3O4
via linkage of the oleic acid surrounding the iron oxide
and NHS bonded to GO. The peak originating from the
functional groups of graphene oxide are also present in the
spectra of B-GO-Fe3O4 and N-GO-Fe3O4 which means
that the starting material (GO) did not undergo the reduc-
tion during the functionalization.
X-ray diffraction (XRD) patterns of graphite, graphene
oxide, B-GO-Fe3O4, and N-GO-Fe3O4 hybrid are shown
in Figure 6. XRD spectrum of graphite is dominated by
intense and narrow peak at 2θ = 26.48o corresponding to
reflection in (002) planes of well-ordered graphene
layers. The lack of this reflection in the diffractogram of
graphene oxide and the difference in the layer distances
of the starting material and the final product confirm
the completion of the oxidation reaction. Positions of
the peaks and their relative intensities shown in XRD
pattern of Fe3O4, B-GO-Fe3O4, and N-GO-Fe3O4 nano-
particle hybrid (Figure 6C,D,E) are consistent with the
standard XRD data for magnetite (ICSD 65339). The
average size of magnetite nanoparticles, calculated from
the Scherrer's equation [52], is about 8 nm, which is
consistent with the from TEM observations.
Thermal gravimetric analysis is a useful tool to deter-
mine the composition of the samples. Figure 7 presents
thermogravimetric (TG) curves of graphite, GO and B-
GO-Fe3O4 and N-GO-Fe3O4 heated in the air. Weight loss
observed at 100°C is associated with the decomposition of
physically adsorbed water. In graphene oxide (Figure 7B),
the next weight loss occurred between 150°C and 300°C
and it can be assigned to the decomposition and eva-
porization of oxygen-containing functional groups. After
reaching 500°C (in graphite at 700°C - Figure 7A), the car-
bon skeleton underwent bulk pyrolysis. TG curves of
nanocomposites (Figure 7C,D) indicate that the amount of
Figure 2 TEM images of Fe3O4 with diameter size distribution (A), B-GO-Fe3O4 (B), and N-GO-Fe3O4 (C).
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and 40% for N-GO-Fe3O4. Both curves show the weight
loss between 150°C and 300°C which means that graphene
oxide did not underwent the reduction during the depos-
ition of magnetite nanoparticles.Raman spectroscopy is a powerful nondestructive tool
to characterize carbonaceous materials, particularly for
distinguishing ordered and disordered crystal structures
of carbon. The significant structural changes occurring
during the functionalization of GO are also reflected in
Figure 3 AFM images and height profiles of B-GO (A), N-GO (B), B-GO-Fe3O4 (C), and N-GO-Fe3O4 (D).
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graphene oxide, B-GO-Fe3O4 and N-GO-Fe3O4. All
spectra exhibit peaks at 1,318 and 1,602 cm−1 corre-
sponded to D and G bands, respectively. The D band is
associated with a certain fraction of sp3 carbon atoms
obtained due to an amorphization of graphite during theoxidation process, whereas the G mode originates from
the in-plane vibration of sp2 carbon atoms [53,54]. The
ratio of ID/IG increases after functionalization of gra-
phene oxide with magnetite nanoparticles in the case of
both hybrid systems indicating successful functionaliza-
tion of the starting material. Due to the presence of
Figure 4 The size distributions of graphene oxide flakes in B-GO (A) and N-GO (B).
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B-GO-Fe3O4 (Figure 8B) and N-GO-Fe3O4 (Figure 8C)
additional peaks in the range of 200 to 300 cm−1 can be
observed.
The good biocompatibility and safety of nanomaterials
is fundamental for its medical application. The first step of
this kind of investigations is in vitro analyses, e.g., mito-
chondrial activity. Here, five different samples have been
examined for their cytocompatibility with L929 mouse fi-
broblasts: two samples of the nanocomposites of graphene
oxide-Fe3O4 nanoparticles with different size distributions
of GO flakes: B-GO-Fe3O4 and N-GO-Fe3O4, two samples
of reference graphene oxide (B-GO and N-GO) and Fe3O4
nanoparticles. The presented biocompatibility study shows
the differences in mitochondrial activity of L929 cells thatFigure 5 FTIR spectra of GO (A), Fe3O4 (B), B-GO-Fe3O4 (C), and N-GO-depend on the type of nanomaterial and concentration
(0.0, 3.125, 6.25, 12.5, 25.0, 50.0, 100.0 μg/mL). As shown
in Figure 9 (mitochondrial activity of the samples with
broader size distribution), no significant cytotoxicity of the
GO-Fe3O4 sample was detected for B-GO-Fe3O4. At the
concentration between 3.125 and 100 μg/mL, minimal re-
duction of the cell mitochondrial activity was observed.
Little reduction of cell viability was noted at a dose of
3.125 μg/mL in B-GO-Fe3O4 sample. In the sample with
25 μg/mL concentration, the mitochondrial activity for
L929 cells was the highest. Interestingly, mitochondrial
activity of the cells when interacting with the pristine-
graphene oxide in the concentration between 50 and
100 μg/mL is significantly reduced. At a dose of 50 μg/
mL, mitochondrial activity was reduced by approximatelyFe3O4 (D).
Figure 6 XRD patterns of graphite (A), GO (B), Fe3O4 (C), B-GO-Fe3O4 (D), and N-GO-Fe3O4 (E).
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tration, cell viability was reduced to approximately 80%.
Lower cytotoxicity was observed at a dose of 6.25 μg/mL
in cell cultures treated with this graphene oxide. It means
that the chemical functionalization of GO and deposition
of Fe3O4 enhance the biocompatibility of the system.
Figure 10 presents cell viability upon interaction with
N-GO-Fe3O4. Here, the best biocompatibility was no-
ticed for the samples at concentration of 12.5 μg/mL for
N-GO-Fe3O4 and N-GO, respectively. These results are
similar to that obtained for samples with broader size
distribution. However, at a dose of 100 μg/mL, the high-
est reduction of the cell viability was noticed. Little re-
duction of cell viability was noted at a dose 3.125 μg/mL
in N-GO-Fe3O4 and GO sample. However, it can be ob-
served that N-GO induces higher reduction of mito-
chondrial activity than hybrid samples. The same trendFigure 7 TG curves of graphite (A), GO (B), B-GO-Fe3O4 (C), and N-GOwas observed in the sample with broad flake size distribu-
tion. It proves that the nanocomposite material is more
biocompatible than pristine GO platforms. Furthermore,
the chemical functionalization of GO and Fe3O4 leads to
enhancement of the biocompatibility of the system and its
independence of the size of GO. In the other study [35],
functionalized GO and GO-Fe3O4 were tested on HeLa
cell line. The WST-1 assay showed differences at mito-
chondrial activity between GO and GO-Fe3O4. Yang et al.
indicated that the GO samples presented higher cytotox-
icity than GO-Fe3O4 [35]. Those results are in agreement
with our study.
The effects of GO on mouse fibroblast cells depend on
GO dose, and as shown in the study of Wang et al. [55],
the effects also depend on the culture time. The most
cytotoxic effect of graphene oxide on human fibroblast
cells (HDF) was observed on the fifth day of culture at-Fe3O4 (D).
Figure 8 Raman spectra of GO (A), B-GO-Fe3O4 (B), and N-GO-Fe3O4 (C).
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ticed in tumor cell lines, e.g., human gastric cancer
MGC803, human breast cancer MCF-7 and MDA-MB-
435, and liver cancer HepG2 [55]. In our study, the ef-
fects of experimental samples on the cell culture were
monitored for 24-h period, but as mentioned earlier, cell
viability was reduced the most, to approximately 60%, at
GO's concentration of 50 μg/mL. Chang et al. [56] using
CCK-8 assay and A549 cells made observation that prep-
aration method of GO has influence of relative cell via-
bility. The influence of different GO samples (s-GO with
smaller size, l-GO with larger size, and m-GO mix) on
the mitochondria activity may vary. m-GO's effect on
cell cultures was insignificant at the concentration rangeFigure 9 Relative viability of fibroblast cell line L929 exposed
to B-GO and B-GO-Fe3O4 hybrid. The cell viability is presented as
percentage of the mean value. Bars represent standard deviation,
and the symbol asterisk indicates statistically significant
difference (p < 0.05).of 100 to 200 μg/mL. When the s-GO was tested, the
cell viability was reduced the most at concentration be-
tween 50 and 200 μg/mL. It also has been noticed that
the difference between some studies might come from
the different sample properties and various cell lines. In-
cubation time can also influence the cell response
[55,57]. In our study, the GO sample with concentration
of 100 μg/mL demonstrated weak toxicity. We suggest
that higher concentration (100 μg/mL) of graphene oxide
may influence on harder GO migration to cell cytoplasm.
We also found that GO material shows relatively good
cytocompatibility at the concentration of 12.5 μg/mL
and that result corresponds to the result obtained by
Wojtoniszak et al. [58].Figure 10 Relative viability of fibroblast cell line L929 exposed
to N-GO and N-GO-Fe3O4 hybrid. The cell viability is presented as
percentage of the mean value. Bars represent standard deviation.
Symbol asterisk indicates statistically significant difference (p < 0.05).
Figure 11 Relative viability of fibroblast cell line L929 exposed
to Fe3O4 nanoparticles. The cell viability is presented as
percentage of the mean value. Bars represent standard deviation,
and symbol asterisk indicates statistically significant difference
(p < 0.05).
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was noticed at concentration of 3.125 and 50 μg/mL
(Figure 11). In the samples of Fe3O4 with concentration
of 6.25 μg/mL, the viability was reduced to 90%. At a
dose of 100 μg/mL, the highest mitochondrial activity
was observed for the Fe3O4 material. Analysing the re-
sults demonstrated by Shundo et al., one can see that
even higher concentration of iron oxide nanoparticles,
between 125 and 1,000 μg/mL, does not reduce the cell
viability [59]. This can be explained by low uptake of
Fe3O4 samples by the cells. Our study suggests that
through the deposition of iron oxide nanoparticles via
covalent linkage on the graphene oxide platform, the up-
take of the nanomaterials is enhanced because the cell
viability was affected more significantly than the pristine
iron oxide nanoparticles. Little toxic effect of Fe3O4 on
Cos-7 monkey kidney cells and GH3 pituitary tumor
cells was observed in other analysis [60,61]. Figure 11
showed no dose-response relationship. Studies per-
formed by Kai et al. indicated that the highest viability of
BEL-7402 human hepatoma was observed when Fe3O4
nanoparticles at the concentration of 0.05 mg/mL were
introduced to the cell culture [62]. When MgNPs-Fe3O4
was tested on A549 cell line for 24 h, no change in the
cell viability was observed. The results of the Alamar
Blue assay showed that treatment with 100 μg/mL of
MgNPs-Fe3O4 for 72 h caused a significant reduction of
cell viability [63].
As shown above, some difficulties in the interpretation
of the obtained results can arise from variety of the fac-
tors that can influence the cell response [63]. Some of
the factors are not clearly determined. Regarding the ef-
fects of graphene oxide and hybrid GO-Fe3O4 on cell
viability, the mechanism is not well explained and still
requires further analysis.
The in vitro studies play key role in exploration of the
nanomaterial properties in biological environment and
interaction with the living matter. The toxicity of the
magnetic nanoparticles on biological entities is highlydependent on a range and combination of factors related
to the properties of those nanoparticles. The physical
properties such as the particle size, shape, and surface
coating can evoke a toxic response by aggregating and
coagulating according to size and shape. The chemical
composition of the particles themselves can be naturally
toxic. Here, we clearly demonstrate that the chemical
functionalization of GO and Fe3O4 is a way to enhance
the biocompatibility of the system and makes the system
independent of the size of graphene oxide. Therefore, we
believe that the obtained product with high cytocompat-
ibility would be suitable for the application in biomedi-
cine, e.g., as a drug carrier and/or in hyperthermia.
Conclusions
We report a facile method of the preparation of graphene
oxide-Fe3O4 nanoparticle hybrid. We prove that it is
possible to increase biocompatibility of graphene oxide
through the deposition of magnetite nanoparticles on the
graphene oxide flakes via chemical interaction. Further-
more, we indicate that the differences in flake size do not
result in different cell viability in contact with our systems.
These results show the potential application of this hybrid
in hyperthermia treatment. Further investigation needs to
be performed in order to prove the safety and efficiency of
these systems in vivo.
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